Adlai Nortye (ANL)

• Market cap: $304M
• 1 day: 4.83%
• 5 days: -15.66%
• 1 month: -11.11%
• 3 months: 468.28%
• 6 months: 362.92%
• Year to date: 497.1%
• 1 year: 258.26%
• 5 years: -45.07%
• 10 years: -45.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Employees: 123